Allele in Women with Breast Cancer Hemochromatosis HFE C 282 Y Increased Prevalence of the Updated

Individuals with the major hemochromatosis (HFE) allele C282Y and iron overload develop hepatocellular and some extrahepatic malignancies at increased rates. No association has been previously reported between the C282Y allele and breast cancer. We hypothesized that due to the pro-oxidant properties of iron, altered iron metabolism in C282Y carriers may promote breast carcinogenesis. Because 1 in 10 Caucasians of Northern European ancestry carries this allele, any impact it may have on breast cancer burden is potentially great. We determined C282Y genotypes in 168 patients who underwent high-dose chemotherapy and blood cell transplantation for cancer: 41 with breast cancer and 127 with predominantly hematological cancers (transplant cohort). Demographic, clinical, and tumor characteristics were reviewed in breast cancer patients. The frequency of C282Y genotypes in breast cancers was compared with the frequency in nonbreast cancers, an outpatient sample from Tennessee (n 169), and a published United States national sample. The frequency of at least one C282Y allele in breast cancers was higher (36.6%, 5 homozygotes/10 heterozygotes) than frequencies in Tennessee (12.7%, P < 0.001), the general population (12.4%, P < 0.001), and similarly selected nonbreast cancers (17.0%, P 0.008). The likelihood of breast cancer in the transplant cohort increased with C282Y allele dose (Ptrend 0.010). These results were supported by the finding in a nontransplant cohort of a higher frequency of C282Y mutations in Caucasian (18.4%, P 0.039) and African-American (8.5%, P 0.005) women with breast cancer than race-specific national frequency estimates. A high prevalence of C282Y alleles in women with breast cancer with and without poor risk features suggests that altered iron metabolism in C282Y carriers may promote the development of breast cancer and/or more aggressive forms of the disease.

[1]  M. Cedars.  Triphasic oral contraceptives: review and comparison of various regimens. , 2002, Fertility and sterility.

[2]  R. Bergeron,et al.  Influence of iron on in vivo proliferation and lethality of L1210 cells. , 1985, The Journal of nutrition.

[3]  J. Sixma,et al.  Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. , 1999, Circulation.

[4]  D. Häussinger,et al.  Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.

[5]  R. Hider,et al.  Non‐transferrin‐bound iron is present in serum of hereditary haemochromatosis heterozygotes , 2000, European journal of clinical investigation.

[6]  J. McManaman,et al.  Alcohol-induced breast cancer: a proposed mechanism. , 1999, Free radical biology & medicine.

[7]  M. Worwood,et al.  Hemochromatosis Gene in Leukemia and Lymphoma , 2002, Leukemia & lymphoma.

[8]  A. Tordai,et al.  High Incidence of Hemochromatosis Gene Mutations in the Myelodysplastic Syndrome: The Budapest Study on 50 Patients , 2003, Acta Haematologica.

[9]  L. Grummer-Strawn,et al.  Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. , 2001, JAMA.

[10]  G. Feldman,et al.  Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African Americans , 1998, American journal of hematology.

[11]  J. Barton,et al.  Inheritance of two HFE mutations in African Americans: Cases with hemochromatosis phenotypes and estimates of hemochromatosis phenotype frequency , 2001, Genetics in Medicine.

[12]  G. Vercellotti,et al.  Tumor cell heme uptake induces ferritin synthesis resulting in altered oxidant sensitivity: possible role in chemotherapy efficacy. , 1993, Cancer research.

[13]  B. Halliwell,et al.  Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. , 1985, Clinical science.

[14]  Fen Wang,et al.  Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. , 2001, Anticancer research.

[15]  J. Liehr,et al.  Role of iron in estrogen-induced cancer. , 2001, Current medicinal chemistry.

[16]  L. Jorde,et al.  Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. , 1996, The New England journal of medicine.

[17]  K. Ebeling,et al.  [Epidemiology of breast cancer]. , 1988, Archiv fur Geschwulstforschung.

[18]  G. Lucarelli,et al.  Correlation between soluble transferrin receptor and serum ferritin levels following bone marrow transplantation for thalassemia , 1995, European journal of haematology.

[19]  K. Barnhart,et al.  Noncontraceptive Benefits and Therapeutic Uses of the Oral Contraceptive Pill , 2001, Seminars in reproductive medicine.

[20]  G. Hallmans,et al.  Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. , 1999, Carcinogenesis.

[21]  B. Markevärn,et al.  Interaction between haemochromatosis and transferrin receptor genes in multiple myeloma , 1998, The Lancet.

[22]  A. Bomford.  Genetics of haemochromatosis , 2002, The Lancet.

[23]  W. Sly,et al.  Molecular aspects of iron absorption and HFE expression. , 2001, Gastroenterology.

[24]  W F Walsh,et al.  Neonatal pulmonary hypertension--urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. , 2001, The New England journal of medicine.

[25]  J. Gutteridge,et al.  Free Radicals and Iron: Chemistry, Biology, and Medicine , 1998 .

[26]  R. Elliott,et al.  Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. , 2001, Anticancer research.

[27]  D. Goldgar.  Population aspects of cancer genetics. , 2002, Biochimie.

[28]  B. Graubard,et al.  Moderate elevation of body iron level and increased risk of cancer occurrence and death , 1994, International journal of cancer.

[29]  Å. Bruce,et al.  The effect of withdrawal of food iron fortification in Sweden as studied with phlebotomy in subjects with genetic hemochromatosis , 1997, European Journal of Clinical Nutrition.

[30]  N. Andrews,et al.  Disorders of iron metabolism. , 1999, The New England journal of medicine.

[31]  M. Björkholm,et al.  The incidence of cancer among blood donors. , 1990, International journal of epidemiology.

[32]  T. Rebbeck.  Inherited predisposition and breast cancer: Modifiers of BRCA1/2‐associated breast cancer risk , 2002, Environmental and molecular mutagenesis.

[33]  N. Polissar,et al.  Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[35]  M. Mattioli,et al.  Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non–iron‐related chronic liver disease , 2001, Hepatology.

[36]  R. Elliott,et al.  Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. , 1999, Anticancer research.

[37]  C. Weinberg,et al.  Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. , 2002, American journal of epidemiology.

[38]  Christopher F. Martin,et al.  Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. , 2003, Journal of the National Cancer Institute.

[39]  R. Press.  Hemochromatosis: a "simple" genetic trait. , 1999, Hospital practice.

[40]  L. E. Anderson,et al.  Hemochromatosis Heterozygotes May Constitute a Radiation-Sensitive Subpopulation , 2000, Radiation research.

[41]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[42]  N. Milman,et al.  Consequences of removing iron fortification of flour on iron status among Danish adults: some longitudinal observations between 1987 and 1994. , 1999, Preventive medicine.

[43]  P. Newcomb,et al.  Hormone replacement therapy in relation to breast cancer. , 2002, JAMA.

[44]  Y. Kohgo,et al.  Transferrin Receptor in Tissue and Serum: Updated Clinical Significance of Soluble Receptor , 2002, International journal of hematology.

[45]  F. Davis,et al.  Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis , 1995, Cancer.

[46]  J. Hopper,et al.  Genetic epidemiology of female breast cancer. , 2001, Seminars in cancer biology.

[47]  W. Sly,et al.  Iron uptake from plasma transferrin by the duodenum is impaired in the Hfe knockout mouse , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  L. E. Anderson,et al.  Oxidative damage in colon and mammary tissue of the HFE-knockout mouse. , 2003, Free radical biology & medicine.

[49]  K. Kowdley,et al.  Hereditary hemochromatosis and cancer risk: more fuel to the fire? , 2001, Gastroenterology.

[50]  J. Vaupel,et al.  Association of mutations in the hemochromatosis gene with shorter life expectancy. , 2001, Archives of internal medicine.

[51]  E. Beutler.  The significance of the 187G (H63D) mutation in hemochromatosis. , 1997, American journal of human genetics.

[52]  E. Weinberg.  Iron withholding: a defense against infection and neoplasia. , 1984, Physiological reviews.

[53]  N. Roodi,et al.  Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. , 1998, Cancer research.

[54]  J. Cuzick,et al.  A Wilcoxon-type test for trend. , 1985, Statistics in medicine.

[55]  W. Sly,et al.  Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.